CoDa's wound care product performs well in clinical trial

01/29/2013 | Interest.co.nz (New Zealand)

CoDa Therapeutics announced that its experimental drug Nexagon to treat chronic venous leg ulcers performed well in midstage clinical trials. The therapy aims to heal wounds faster and increase the incidence of wound healing compared with existing treatment options.

View Full Article in:

Interest.co.nz (New Zealand)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ